Cingulate Inc. CING
We take great care to ensure that the data presented and summarized in this overview for Cingulate Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CING
Top Purchases
Top Sells
About CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Insider Transactions at CING
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2024
|
Laurie Myers EVP and COO |
SELL
Open market or private sale
|
Direct |
202
-100.0%
|
$808
$4.17 P/Share
|
|
Apr 11
2024
|
Peter J. Werth Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,036,008
+39.31%
|
-
|
|
Sep 15
2023
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+9.9%
|
$0
$0.67 P/Share
|
|
Aug 11
2023
|
Peter J. Werth Director |
BUY
Open market or private purchase
|
Indirect |
1,823,155
+39.45%
|
$0
$0.55 P/Share
|
|
May 15
2023
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+4.71%
|
$2,000
$1.01 P/Share
|
|
May 12
2023
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
4,000
+9.41%
|
$4,000
$1.08 P/Share
|
|
Dec 16
2022
|
Shane J. Schaffer Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+19.42%
|
$10,000
$1.02 P/Share
|
|
Dec 14
2022
|
Shane J. Schaffer Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,267
+29.64%
|
$13,267
$1.01 P/Share
|
|
Dec 14
2022
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
7,548
+17.95%
|
$0
$0.99 P/Share
|
|
Dec 13
2022
|
Shane J. Schaffer Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,733
+8.68%
|
$1,733
$1.01 P/Share
|
|
Dec 13
2022
|
Peter J. Werth Director |
BUY
Open market or private purchase
|
Indirect |
28,934
+2.88%
|
$0
$0.98 P/Share
|
|
Nov 29
2022
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
1,530
+5.37%
|
$0
$0.98 P/Share
|
|
Nov 28
2022
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
3,487
+12.06%
|
$0
$0.98 P/Share
|
|
Nov 23
2022
|
Laurie Myers EVP and COO |
BUY
Open market or private purchase
|
Direct |
1,111
+2.25%
|
$0
$0.9 P/Share
|
|
Nov 23
2022
|
Craig S. Gilgallon EVP and General Counsel |
BUY
Open market or private purchase
|
Direct |
3,575
+27.24%
|
$0
$0.84 P/Share
|
|
Nov 22
2022
|
Gregg Wm Givens Director |
BUY
Open market or private purchase
|
Direct |
85,000
+35.52%
|
$0
$0.88 P/Share
|
|
Sep 08
2022
|
Jennifer L. Callahan SVP and CFO |
BUY
Open market or private purchase
|
Direct |
3,500
+13.76%
|
$3,500
$1.5 P/Share
|
|
Sep 06
2022
|
Peter J. Werth Director |
BUY
Open market or private purchase
|
Indirect |
74,500
+7.3%
|
$74,500
$1.52 P/Share
|
|
Sep 01
2022
|
Laurie Myers EVP and COO |
BUY
Open market or private purchase
|
Direct |
636
+1.33%
|
$636
$1.57 P/Share
|
|
Jun 01
2022
|
Laurie Myers EVP and COO |
BUY
Open market or private purchase
|
Direct |
200
+0.43%
|
$200
$1.18 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.04M shares |
|---|
| Open market or private sale | 202 shares |
|---|